Last reviewed · How we verify
NBM-BMX Capsule
At a glance
| Generic name | NBM-BMX Capsule |
|---|---|
| Sponsor | Novelwise Pharmaceutical Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma (PHASE1, PHASE2)
- NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma (PHASE1, PHASE2)
- A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer (PHASE1)
- A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NBM-BMX Capsule CI brief — competitive landscape report
- NBM-BMX Capsule updates RSS · CI watch RSS
- Novelwise Pharmaceutical Corporation portfolio CI